Literature DB >> 21788900

Blau syndrome revisited.

Carlos D Rose1, Tammy M Martin, Carine H Wouters.   

Abstract

PURPOSE OF REVIEW: Blau syndrome is a monogenic disease resulting from mutations in nucleotide oligomerization domain 2 (NOD2) and is phenotypically characterized by granulomatous polyarthritis and uveitis. Not only there has been significant progress in disease characterization but also the biological pathways associated with NOD2 and related proteins of the innate immunity are better understood. RECENT
FINDINGS: The phenotype of Blau syndrome has proven to be more complex than initially thought. A discussion on those manifestations will be provided in the clinical sections of this review. As more patients and pedigrees are found new mutations in the NOD2 gene have emerged and we discuss them in some detail. Due to its importance in Crohn's disease NOD2 has become the focus of intense research. A brief review of more recent advances in relevant pathways is presented and published reviews referenced for the interested reader. The granulomatous character of Blau syndrome provides an opportunity to look at possible pathogenic effects of NOD2 'gain of function'. New immunohistochemical data are briefly reviewed as well.
SUMMARY: Elucidation of downstream effects of NOD2 mutations could provide valuable clues to mechanisms of arthritis and uveitis in general as well as granulomatous diseases in particular.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788900     DOI: 10.1097/BOR.0b013e328349c430

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  24 in total

Review 1.  Granulomas in the gastrointestinal tract: deciphering the Pandora's box.

Authors:  Ian Brown; Marian Priyanthi Kumarasinghe
Journal:  Virchows Arch       Date:  2017-08-04       Impact factor: 4.064

Review 2.  Genetically defined autoinflammatory diseases.

Authors:  A A de Jesus; R Goldbach-Mansky
Journal:  Oral Dis       Date:  2016-04-14       Impact factor: 3.511

Review 3.  Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.

Authors:  Gina A Montealegre Sanchez; Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Rheum Dis Clin North Am       Date:  2013-09-21       Impact factor: 2.670

Review 4.  The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

Authors:  Luca Cantarini; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Luisa Costa; Giacomo Emmi; Elena Silvestri; Flora Magnotti; Maria Cristina Maggio; Eugenia Prinzi; Giuseppe Lopalco; Bruno Frediani; Rolando Cimaz; Mauro Galeazzi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2014-06-24       Impact factor: 2.980

Review 5.  Lighting the fires within: the cell biology of autoinflammatory diseases.

Authors:  Heiyoung Park; Ariel Bulua Bourla; Daniel L Kastner; Robert A Colbert; Richard M Siegel
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

6.  Aberrant interleukin-1 signalling does not increase susceptibility of mice to NOD2-dependent uveitis.

Authors:  Ellen J Lee; Jordan J Allensworth; Jenna S Clowers; Holly L Rosenzweig
Journal:  Clin Exp Ophthalmol       Date:  2014-10-30       Impact factor: 4.207

Review 7.  Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature.

Authors:  Francesco La Torre; Giovanni Lapadula; Luca Cantarini; Orso Maria Lucherini; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2014-01-21       Impact factor: 2.980

8.  Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Authors:  Curt D Haffner; Adam K Charnley; Christopher J Aquino; Linda Casillas; Máire A Convery; Julie A Cox; Mark A Elban; Nicole C Goodwin; Peter J Gough; Pamela A Haile; Terry V Hughes; Beth Knapp-Reed; Constantine Kreatsoulas; Ami S Lakdawala; Huijie Li; Yiqian Lian; David Lipshutz; John F Mehlmann; Michael Ouellette; Joseph Romano; Lisa Shewchuk; Arthur Shu; Bartholomew J Votta; Huiqiang Zhou; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2019-10-11       Impact factor: 4.345

Review 9.  Monogenic autoinflammatory diseases: concept and clinical manifestations.

Authors:  Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Clin Immunol       Date:  2013-04-09       Impact factor: 3.969

Review 10.  IL-1 blockade in autoinflammatory syndromes.

Authors:  Adriana A Jesus; Raphaela Goldbach-Mansky
Journal:  Annu Rev Med       Date:  2014       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.